Life After Woodcock: US FDA Drug Center’s Leadership Transition

 
• By Michael McCaughan

The elevation of the US FDA’s top drug regulator, Janet Woodcock, to oversee COVID-19 response efforts is being framed a temporary step as part of the crisis response. But it is also a try-out for the most significant leadership transition in drug regulation in the US in a generation.

Woodcock_Janet_1200x675
COVID-19 initiatives mark the third time Woodcock has moved up into the commissioner’s office since she first became CDER director in 1994.

More from US FDA

More from Agency Leadership